Brentuximab vedotin (Adcetris®) for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy. This is a license extension.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||07/02/2018|
|Rapid review completed||06/03/2018|
|Rapid Review outcome||Full pharmacoeconomic assessment recommended|
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.